Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Short Interest Down 85.9% in February

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) was the target of a significant drop in short interest in the month of February. As of February 13th, there was short interest totaling 27,138 shares, a drop of 85.9% from the January 29th total of 192,649 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio is presently ∞ days. Based on an average daily trading volume, of 0 shares, the short-interest ratio is presently ∞ days.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating on shares of Hansa Biopharma AB (publ) in a research note on Thursday, February 12th. Wedbush initiated coverage on shares of Hansa Biopharma AB (publ) in a research report on Wednesday, January 7th. They issued an “outperform” rating for the company. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, Hansa Biopharma AB (publ) currently has a consensus rating of “Buy”.

Hansa Biopharma AB (publ) Trading Down 36.7%

OTCMKTS:HNSBF traded down $1.68 during trading hours on Friday, reaching $2.90. The company’s stock had a trading volume of 350 shares, compared to its average volume of 10,133. Hansa Biopharma AB has a one year low of $2.73 and a one year high of $4.58. The business’s 50-day moving average is $2.91 and its 200-day moving average is $3.19.

Hansa Biopharma AB (publ) Company Profile

Hansa Biopharma AB (publ) is a clinical‐stage biopharmaceutical company headquartered in Lund, Sweden, focused on the development and commercialization of precision immunomodulatory therapies for rare diseases. The company’s proprietary platform centers on highly specific bacterial enzymes that selectively cleave immunoglobulin G (IgG) antibodies, offering a novel approach to desensitization and immunomodulation in transplant and autoimmune settings.

The lead asset, imlifidase (Idefirix), is an enzyme therapeutic designed to rapidly inactivate donor‐specific antibodies in highly sensitized kidney transplant patients.